Diabetes Mellitus and Cardiovascular Disease

The Diabetes Educator

Volumn 27, Issue 1, 2001, Pages 28-34

  Nash, David T ^a,b  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^b Presidential Plaza ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC ANGIOPATHY; HUMAN; HYPERTENSION; PATHOPHYSIOLOGY; PATIENT COMPLIANCE;

CARDIOVASCULAR DISEASES; CORONARY DISEASE; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; HUMANS; HYPERTENSION; PATIENT COMPLIANCE;

EID: 0035240253     PISSN: 01457217     EISSN: None     Source Type: Journal    
DOI: 10.1177/014572170102700104     Document Type: Article

References (11)

1. Herrick JB. Clinical features of sudden obstruction of the arteries. JAMA. 1912; 59:2010-2015.
2. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Survival Study (4S) Group. Lancet. 1994;344: 1383-1389.
3. Shepard J, Cobbe SM, Ford I, et al, for the West of Scotland Coronary Primary Prevention Group. Promotion of coronary artery disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995; 333:1301-1307.
4. Sacks FM, Pfeffer MA, Moye AA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;334: 1001-1009.
5. The Long Term Intervention With Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339: 1349-1358.
6. Downs JR, Clearfield M, Weis S, et al, for the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol revels. JAMA. 1998;279: 1615-1622.
7. Campbell NC, Thain J, Deans HG. Secondary prevention in coronary heart disease: baseline survey of provisions in general practice. Br Med J. 1998;316: 1400-1401.
8. Campbell JA. Aspirin therapy in diabetes. Diabetes Care. 1996;20: 1767-1771.
9. Ikonomids I, Andrepotti F, Stephanadis C, et al. Reduction of cytokines and platelet aggregation by aspirin causes reduction of daily life ischemia in stable angina [abstract]. Circulation. 1999;100:1387-1387.
10. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive bloodpressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment(HOT) Randomized Trial. Lancet. 1998;351:1755-1762.
11. Antiplatelet Trialist Collaboration. Collaborative overview of randomized trials of antiplatelet therapy: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J. 1994;308:81-106.